{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:39:53Z","timestamp":1793083193864,"version":"4.5.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NIA\/NIH","award":["K01 AG079680"],"award-info":[{"award-number":["K01 AG079680"]}]},{"name":"PD\/PI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Selective androgen receptor modulators (SARMs) are a novel class of compounds engineered to confer the anabolic benefits of testosterone such as increased muscle and bone mass while minimizing undesirable androgenic effects. Their tissue-selective activity and oral availability have sparked significant interest in their potential applications for conditions like muscle wasting, osteoporosis, hypogonadism, and frailty. We outline the chemical underpinnings of SARMs, their clinical promise, and the major challenges that have limited their regulatory approval to date. Although multiple SARMs have shown efficacy in increasing lean body mass in clinical trials, few have demonstrated consistent improvements in functional outcomes such as strength or mobility. Safety concerns, particularly regarding hepatotoxicity and cardiovascular risk, remain incompletely resolved. Nevertheless, a subset of SARMs is being actively evaluated for indications directly related to aging and sarcopenia. We conclude that SARMs are likely to enter clinical practice in select niches of men and women, especially among the frail, the elderly, or individuals with excessive loss of lean body mass. However, widespread approval will depend on future trials demonstrating both efficacy and long-term safety.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf700","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:42:54Z","timestamp":1770295374000},"page":"e1467-e1471","source":"Crossref","is-referenced-by-count":4,"title":["Will Selective Androgen Receptor Modulators Ever Reach The Clinic?"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-0543","authenticated-orcid":false,"given":"Jenny Pena","family":"Dias","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-6061","authenticated-orcid":false,"given":"Adrian S","family":"Dobs","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"1","key":"2026042119565822700_dgaf700-B1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.sxmr.2018.09.006","article-title":"Selective androgen receptor modulators: current knowledge and clinical applications","volume":"7","author":"Solomon","year":"2019","journal-title":"Sex Med Rev"},{"issue":"3","key":"2026042119565822700_dgaf700-B2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"S2","key":"2026042119565822700_dgaf700-B3","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.21037\/tau.2019.11.02","article-title":"Selective androgen receptor modulators: the future of androgen therapy?","volume":"9","author":"Christiansen","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2026042119565822700_dgaf700-B4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","article-title":"Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging","volume":"2","author":"Bhasin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"2026042119565822700_dgaf700-B5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/gerona\/gls078","article-title":"The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men","volume":"68","author":"Basaria","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"2026042119565822700_dgaf700-B6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/j.1939-4640.2001.tb02570.x","article-title":"Testosterone supplementation in older men: a rational idea whose time has not yet come","volume":"22","author":"Bhasin","year":"2001","journal-title":"J Androl"},{"issue":"4","key":"2026042119565822700_dgaf700-B7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026042119565822700_dgaf700-B8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/13543784.2020.1777275","article-title":"Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials","volume":"29","author":"Fonseca","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2026042119565822700_dgaf700-B9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/ml1002508","article-title":"Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140","volume":"2","author":"Miller","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"2026042119565822700_dgaf700-B10","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/jcsm.13321","article-title":"Physical function endpoints in cancer cachexia clinical trials: systematic review 1 of the cachexia endpoints series","volume":"14","author":"McDonald","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"2026042119565822700_dgaf700-B11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12603-013-0335-x","article-title":"A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia","volume":"17","author":"Papanicolaou","year":"2013","journal-title":"J Nutr Health Aging"},{"issue":"2","key":"2026042119565822700_dgaf700-B12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11095-006-9152-9","article-title":"Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats","volume":"24","author":"Kearbey","year":"2007","journal-title":"Pharm Res"},{"key":"2026042119565822700_dgaf700-B13","doi-asserted-by":"crossref","first-page":"114119","DOI":"10.1016\/j.ejmech.2022.114119","article-title":"Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)","volume":"230","author":"Xie","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2026042119565822700_dgaf700-B14","first-page":"232","article-title":"Selective androgen receptor modulators as function promoting therapies","volume":"12","author":"Bhasin","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2026042119565822700_dgaf700-B15","doi-asserted-by":"crossref","first-page":"108753","DOI":"10.1016\/j.steroids.2020.108753","article-title":"Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: a narrative review","volume":"164","author":"Machek","year":"2020","journal-title":"Steroids"},{"issue":"1","key":"2026042119565822700_dgaf700-B16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/en.2008-0674","article-title":"Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception","volume":"150","author":"Jones","year":"2009","journal-title":"Endocrinology"},{"issue":"1","key":"2026042119565822700_dgaf700-B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clbc.2021.08.003","article-title":"A first-in-human phase 1 study of a novel selective androgen receptor modulator (SARM), RAD140, in ER+\/HER2- metastatic breast cancer","volume":"22","author":"LoRusso","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"2026042119565822700_dgaf700-B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","article-title":"Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial","volume":"25","author":"Palmieri","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026042119565822700_dgaf700-B19","doi-asserted-by":"crossref","first-page":"e151719","DOI":"10.1172\/JCI151719","article-title":"Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth","volume":"131","author":"Nyquist","year":"2021","journal-title":"J Clin Invest"},{"key":"2026042119565822700_dgaf700-B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.06.016","article-title":"In vitro anti-carcinogenic effect of andarine as a selective androgen receptor modulator on MIA-PaCa-2 cells by decreased proliferation and cell-cycle arrest at G0\/G1 phase","volume":"671","author":"Boluk","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"2026042119565822700_dgaf700-B21","first-page":"177","article-title":"Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes","volume":"17","author":"Muta","year":"2019","journal-title":"Biochem Biophys Rep"},{"issue":"8","key":"2026042119565822700_dgaf700-B22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/clinem\/dgab361","article-title":"A selective androgen receptor modulator (OPK-88004) in prostate cancer survivors: a randomized trial","volume":"106","author":"Pencina","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042119565822700_dgaf700-B23","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1038\/s41598-024-52662-8","article-title":"Shorter self-reported sleep duration is associated with worse virtual spatial navigation performance in men","volume":"14","author":"Yavuz","year":"2024","journal-title":"Sci Rep"},{"issue":"1-3","key":"2026042119565822700_dgaf700-B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2013.10.042","article-title":"A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate","volume":"720","author":"Akita","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2026042119565822700_dgaf700-B25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/cn400133s","article-title":"Nonsteroidal selective androgen receptor modulators and selective estrogen receptor beta agonists moderate cognitive deficits and amyloid-beta levels in a mouse model of Alzheimer's disease","volume":"4","author":"George","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"16","key":"2026042119565822700_dgaf700-B26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"2026042119565822700_dgaf700-B27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/SPC.0000000000000015","article-title":"Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer","volume":"7","author":"Dalton","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"2026042119565822700_dgaf700-B28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thorax-2021-218360","article-title":"Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial","volume":"78","author":"Mohan","year":"2023","journal-title":"Thorax"},{"issue":"1","key":"2026042119565822700_dgaf700-B29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-022-00730-y","article-title":"What's new in therapy for male androgenetic alopecia?","volume":"24","author":"Saceda-Corralo","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2026042119565822700_dgaf700-B30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2474-15-291","article-title":"Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization","volume":"15","author":"Blanque","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"2026042119565822700_dgaf700-B31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/hep4.1456","article-title":"Drug-induced liver injury by selective androgenic receptor modulators","volume":"4","author":"Flores","year":"2020","journal-title":"Hepatol Commun"},{"issue":"4","key":"2026042119565822700_dgaf700-B32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jpr3.70041","article-title":"Drug-induced liver injury associated with selective androgen receptor modulators in an adolescent patient","volume":"6","author":"Katibian","year":"2025","journal-title":"JPGN Rep"},{"issue":"8","key":"2026042119565822700_dgaf700-B33","doi-asserted-by":"crossref","first-page":"bvac099","DOI":"10.1210\/jendso\/bvac099","article-title":"Effect of selective androgen receptor modulator on cholesterol efflux capacity, size, and subspecies of HDL particles","volume":"6","author":"Guo","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026042119565822700_dgaf700-B34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/jox13020017","article-title":"Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users","volume":"13","author":"Vignali","year":"2023","journal-title":"J Xenobiot"},{"issue":"2","key":"2026042119565822700_dgaf700-B35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/00913847.2022.2108352","article-title":"Social media may cause emergent SARMs abuse by athletes: a content quality analysis of the most popular YouTube videos","volume":"51","author":"Vasireddi","year":"2023","journal-title":"Phys Sportsmed"},{"issue":"6","key":"2026042119565822700_dgaf700-B36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00774-023-01453-8","article-title":"Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis","volume":"41","author":"Hoffmann","year":"2023","journal-title":"J Bone Miner Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf700\/66844447\/dgaf700.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1467\/66844447\/dgaf700.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/e1467\/66844447\/dgaf700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:57:05Z","timestamp":1776815825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/e1467\/8471602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf700","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,11]]}}}